PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Frost & Sullivan Identifies Increased Prevalence of Non-communicable Diseases as Key Driving Factor in Growth of the WA Pharmaceutical Industry - New analysis from Frost & Sullivan, Pharmaceutical Industry in Ghana and Nigeria, earned revenues of $970.0 million in 2009 and estimates this to reach $2,307.2 million in 2016
Frost & Sullivan Identifies Increased Prevalence of Non-communicable Diseases as Key Driving Factor in Growth of the WA Pharmaceutical Industry

 

NewswireToday - /newswire/ - Cape Town, South Africa, 2011/03/30 - New analysis from Frost & Sullivan, Pharmaceutical Industry in Ghana and Nigeria, earned revenues of $970.0 million in 2009 and estimates this to reach $2,307.2 million in 2016.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

With the adoption of a more western lifestyle characterised by less healthy diets and more sedentary activities across West African countries like Nigeria and Ghana, the incidence of non-communicable diseases, particularly hypertension and diabetes, have increased. As the demand for chronic medicines for these conditions surges, lucrative market opportunities, particularly in the generic market, have opened up.

New analysis from Frost & Sullivan (pharma.frost.com), Pharmaceutical Industry in Ghana and Nigeria, earned revenues of $970.0 million in 2009 and estimates this to reach $2,307.2 million in 2016. The following therapeutic segments are covered in the research: anti-infectives, cardiovascular, diabetes, respiratory, oncology and central nervous system.

"The dual burden of communicable and non-communicable diseases in Ghana and Nigeria is the main driver for growth of the pharmaceutical industry in the region," notes Frost & Sullivan Research Analyst Tinotenda Sachikonye. "Second and third, only to anti-infectives, in terms of contribution to the 2009 annual pharmaceutical industry revenues in Ghana and Nigeria were medicines for cardiovascular conditions and diabetes."

Treatment for diabetes and cardiovascular conditions such as hypertension is typically chronic, thereby creating a continual demand for diabetes and hypertension medicines. Several foreign generic companies have entered the West African market and more local manufacturers are focussing on medicines for hypertension and diabetes.

However, as the major proportion of consumers in Ghana and Nigeria are price- sensitive, competition with low-cost Asian generics is a challenge for the majority of participants in the market. The cost of conducting business for local manufacturers is particularly high.

"Price is an important purchasing criterion for the Ghana National Health Insurance (NHI) which covers 66.4 per cent of the population in Ghana and the NHI will only pay for generics," explains Sachikonye. "Additionally, government tenders in both countries are awarded mainly on the basis of price."

It is important that companies in this market identify their target customers and differentiate themselves accordingly. Although the majority of consumers in the region are price sensitive, several others are brand loyal and willing to pay the cost for their preferred brands.

"Although pricing is a major factor to success in Ghana and Nigeria, other factors such as having good quality products, having a robust distribution network, good marketing strategies and brand recognition are equally important," concludes Sachikonye. "Pharmaceutical companies can leverage these factors to attain a competitive position in the market."

Pharmaceutical Industry in Ghana and Nigeria is part of the Pharmaceuticals & Biotechnology Growth Partnership Services programme, which also includes research in the following markets: Pharmaceutical Industry in East Africa, Pharmaceutical Industry in key SADC countries, Healthcare Overview in Mozambique, Healthcare Overview in Zimbabwe and Healthcare Overview in Angola. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

If you are interested in more information about this study, please send an email to Christie Cronje, Corporate Communications, at christie.cronje[.]frost.com, with your full name, company name, title, telephone number, company email address, company website, city, state and country.

About Frost & Sullivan
Frost & Sullivan (frost.com), the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents.

Pharmaceutical Industry in Ghana and Nigeria / M65E

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Frost & Sullivan Identifies Increased Prevalence of Non-communicable Diseases as Key Driving Factor in Growth of the WA Pharmaceutical Industry

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Christie Cronje 
+27 21 680 3566 christie.cronje[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  NAKIVO, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)